In 30 adults with difficult-to-treat depression and low-grade inflammation, one tocilizumab infusion did not significantly improve somatic depression symptoms at day 14 vs placebo (adjusted mean difference −0.12); no results were significant. No serious adverse events.
RCTn = 30
Foley et al. Interleukin 6 as a Treatment Target for Depression: A Proof-of-Concept Randomized Clinical Trial